Infleqtion Lands $55 Million Quantum Contract as Citron Calls It the Most Mispriced Stock
NEW YORK, April 19 —
Infleqtion (INFQ) hit an all-time high after a $55M contract win and a rare bullish endorsement from Citron Research.
- Infleqtion secured a $55M contract as a key quantum supplier, nearly 2x its $32mn TTM revenue
- Forward P/E sits at -114.3x, meaning the company is burning cash well past any reasonable breakeven horizon
- Next catalyst: upcoming 13F filings will show whether institutional money followed Citron's thesis or if this remains a retail-driven trade
What Actually Happened
Two things landed at once, and the combination matters more than either one alone. The $55M contract validates Infleqtion as a real supplier in the quantum stack, not just a research-stage company pitching slide decks. A contract worth 1.7x your trailing twelve-month revenue is material by any definition.
Then Citron Research, best known for short-selling campaigns that have cratered stocks from Valeant to GameStop, publicly called INFQ the most obvious mispricing in quantum. That is a sharp pivot for a firm whose brand is built on spotting overvaluation, not undervaluation. When the loudest bear in the room turns bullish on your sector's most speculative corner, retail pays attention. And it did.
The Catch
A $55M contract sounds large against $32mn in TTM revenue, but the details matter enormously, and we don't have them yet. Who is the customer? Over how many years does $55M get recognized? A five-year deal drops to $11M annually, which is solid growth but not transformational. A two-year deal changes the math entirely.
The forward P/E of -114.3x is not a misprint. Infleqtion is deeply unprofitable and priced entirely on the promise that quantum computing's commercial moment is near. Citron's endorsement is a sentiment catalyst, not a fundamental one. The firm does not manage a fund. It publishes research. The actual test is whether large institutions add INFQ in the next round of 13F disclosures.
Bottom Line
This is a better story today than it was last week. A real contract plus a high-profile endorsement is more substance than most quantum names can point to. But at $17.42 on $32mn in revenue and no path to near-term profitability, you are buying a narrative, not a business. The stock's next move depends on whether the $55M contract's details justify the current price or reveal a slower revenue ramp than the market assumed.
Infleqtion does not yet have a Basis Report. Generate a full INFQ investment report here to dig into the financials beyond the headline.
Basis Report does not hold positions in securities discussed. This is not investment advice.